Abstract
BACKGROUND: Accurate characterization of glioma is crucial for clinical decision making. A delineation of the tumor is also desirable in the initial decision stages but is time-consuming. Previously, deep learning methods have been developed that can either non-invasively predict the genetic or histological features of glioma, or that can automatically delineate the tumor, but not both tasks at the same time. Here, we present our method that can predict the molecular subtype and grade, while simultaneously providing a delineation of the tumor.
METHODS: We developed a single multi-task convolutional neural network that uses the full 3D, structural, pre-operative MRI scans to predict the IDH mutation status, the 1p/19q co-deletion status, and the grade of a tumor, while simultaneously segmenting the tumor. We trained our method using a patient cohort containing 1508 glioma patients from 16 institutes. We tested our method on an independent dataset of 240 patients from 13 different institutes.
RESULTS: In the independent test set we achieved an IDH-AUC of 0.90, an 1p/19q co-deletion AUC of 0.85, and a grade AUC of 0.81 (grade II/III/IV). For the tumor delineation, we achieved a mean whole tumor DICE score of 0.84.
CONCLUSIONS: We developed a method that non-invasively predicts multiple, clinically relevant features of glioma. Evaluation in an independent dataset shows that the method achieves a high performance and that it generalizes well to the broader clinical population. This first of its kind method opens the door to more generalizable, instead of hyper-specialized, AI methods.
Original language | English |
---|---|
Pages (from-to) | 279-289 |
Number of pages | 11 |
Journal | Neuro-Oncology |
Volume | 25 |
Issue number | 2 |
Early online date | 5 Jul 2022 |
DOIs | |
Publication status | Published - 1 Feb 2023 |
Bibliographical note
Funding:S.R.v.d.V and F.I. acknowledge funding by the Dutch Cancer Society
(KWF project number EMCR 2015-7859). This project has received
funding from the European Union’s Horizon 2020 Research and
Innovation Programme under grant agreement No 952103.
© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.
Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.